Climb Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLYM research report →
Companyeliemtx.com
Climb Bio, Inc. , a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
- CEO
- Aoife Brennan BCh MMSc
- IPO
- 2021
- Employees
- 17
- HQ
- Wellesley Hills, DE, US
Price Chart
Valuation
- Market Cap
- $717.30M
- P/E
- -13.59
- P/S
- 0.00
- P/B
- 4.85
- EV/EBITDA
- -12.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.46%
- ROIC
- -40.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-59,851,000 · 19.01%
- EPS
- $-0.88 · 42.48%
- Op Income
- $-67,883,000
- FCF YoY
- -250.48%
Performance & Tape
- 52W High
- $12.48
- 52W Low
- $1.16
- 50D MA
- $8.64
- 200D MA
- $4.59
- Beta
- 0.05
- Avg Volume
- 703.19K
Get TickerSpark's AI analysis on CLYM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 29, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,106,000 |
| Feb 25, 26 | Thomas Stephen Basil | sell | 33,687 |
| Feb 26, 26 | Thomas Stephen Basil | sell | 16,313 |
| Feb 12, 26 | Thomas Stephen Basil | sell | 90,000 |
| Feb 13, 26 | Thomas Stephen Basil | sell | 10,000 |
| Jan 6, 26 | Brennan Aoife | other | 700,000 |
| Jan 6, 26 | Wilson Perrin Megan | other | 300,000 |
| Jan 6, 26 | ALTSCHULLER Susan | other | 142,500 |
| Jan 6, 26 | Driscoll Cindy | other | 100,000 |
| Jan 5, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 7,111 |
Our CLYM Coverage
We haven't published any research on CLYM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLYM Report →